摘要
众所周知干扰素应答在慢性丙型感染病毒感染中是下调的。特别是几项研究表示那些患有慢性HCV感染具有干扰素刺激基因的高自然水平的的患者不能实现病毒的清除以及对于聚乙二醇化干扰素α和利巴韦林的治疗具有较差的应答性。与其他HCV感染患者相比,负责较高内源性的ISG表达的病毒和(或)宿主因子仍有待确定。然而, III型干扰素特别是新发现的拉姆达干扰素(L)4基因,似乎在驱动ISG反应和促进HSV持久性的建立中起主要作用。本综述的重点阐述近期ISG应答和IFNλ基因因子是如何影响HCV感染的临床结果,强调了在当前抗病毒治疗中使用直接抗病毒剂的影响。
关键词: 干扰素,干扰素刺激基因,白细胞介素-28B, 干扰素拉姆达4, 直接抗病毒剂, 先天免疫
Current Drug Targets
Title:Role of Interferons in Chronic Hepatitis C Infection
Volume: 18 Issue: 7
关键词: 干扰素,干扰素刺激基因,白细胞介素-28B, 干扰素拉姆达4, 直接抗病毒剂, 先天免疫
摘要: It is known that the production of and/or response to interferon (IFN) are deregulated during chronic hepatitis C virus (HCV) infection. In particular, several studies have shown that patients with chronic HCV infection who have a high natural level of IFN-stimulated genes (ISGs) do not achieve viral clearance and have a poor response to treatment with pegylated IFNα and ribavirin. The viral and/or host factors that are responsible for the higher endogenous ISGs expression in some HCV infected patients compared to others remain to be determined. However, type III IFNs, and in particular the new discovered IFN lambda (L) 4 Gene, appear to play a dominant role in driving ISGs response and in contributing to the establishment of HCV persistence. This review focuses on recent studies on how the ISGs response and the IFNλ genetic factors (interleukin-28B and IFNL4) affect the clinical outcome of HCV infection highlighting their impact in the current antiviral therapies with direct acting antiviral agents.
Export Options
About this article
Cite this article as:
Role of Interferons in Chronic Hepatitis C Infection, Current Drug Targets 2017; 18 (7) . https://dx.doi.org/10.2174/1389450117666160201112632
DOI https://dx.doi.org/10.2174/1389450117666160201112632 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
Call for Papers in Thematic Issues
Drug-Targeted Approach with Polymer Nanocomposites for Improved Therapeutics
Polymer nanocomposites have been recognized as an advanced and cutting-edge technique in drug targeting administration. These materials combine the unique features of nanoparticles with the adaptability of polymers to produce highly personalized drug administration devices. Integrating nanoparticles containing pharmaceuticals into a polymer matrix enables researchers to regulate the rates at ...read more
RNA Molecules in the Treatment of Human Diseases
Messenger and non-coding RNAs, including long and small transcripts, are mediators of gene expression. Gene expression at the RNA level shows significant aberrations in human diseases, including cancer, leukemia, lymphoma, cardiovascular diseases, and neurological disorders. Human transcripts serve either as biomarkers of diagnosis, prognosis, prediction of treatment response and/or therapy ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
UDP-Glucuronosyltransferases
Current Drug Metabolism Small Diverse Antioxidant Functionalities for Oxidative Stress Disease Drug Discovery
Mini-Reviews in Medicinal Chemistry Cytokine Network in Inflammatory Bowel Disease
Current Drug Targets - Inflammation & Allergy Aspirin as a Chemoprevention Agent for Colorectal Cancer
Current Drug Metabolism The Ubiquitin Proteasome System as a Potential Target for the Treatment of Neurodegenerative Diseases
Current Pharmaceutical Design Natural Product-derived Phytochemicals as Potential Inhibitors of Angiotensin Converting Enzyme 2 (ACE2): Promising Drug Candidates for COVID-19
Current Drug Therapy Lipoxygenases - A Challenging Problem in Enzyme Inhibition and Drug Development
Current Enzyme Inhibition A Critical Review Based on Preclinical Studies of Medicinal Plants for the Management of Alzheimer’s Disease
Current Bioactive Compounds Independent Relationship of Osteocalcin Circulating Levels with Obesity, Type 2 Diabetes, Hypertension, and HDL Cholesterol
Endocrine, Metabolic & Immune Disorders - Drug Targets Introduction: Hepatocyte Growth Factor and Met Receptor, from Discovery to Therapeutic Implications
Current Signal Transduction Therapy Cytomegalovirus Prophylaxis in Solid Organ Transplantation
Current Medicinal Chemistry Recent Advances in the Molecular Pathogenesis of Dystonia-Plus Syndromes and Heredodegenerative Dystonias
Current Neuropharmacology New Ferrocene Compounds as Selective Cyclooxygenase (COX-2) Inhibitors: Design, Synthesis, Cytotoxicity and Enzyme-inhibitory Activity
Anti-Cancer Agents in Medicinal Chemistry Danger-Detector NKG2D: Immunosurveillance of Induced Self and Modulation by Cytokines and Soluble Ligands
Current Medicinal Chemistry - Anti-Inflammatory & Anti-Allergy Agents An Innovative Approach in Nanotechnology-based Delivery System for the Effective Management of Psoriasis
Current Pharmaceutical Design Neutrophil Extracellular Traps in Cerebral Ischemia/Reperfusion Injury: Friend and Foe
Current Neuropharmacology Aminoglycoside Nephrotoxicity
Current Drug Targets - Infectious Disorders Zinc in the Glutamatergic Theory of Depression
Current Neuropharmacology Corticotropin-Releasing Factor Receptor Antagonists in Affective Disorders and Drug Dependence - An Update
CNS & Neurological Disorders - Drug Targets The Heat Shock Protein 90 Chaperone Complex: An Evolving Therapeutic Target
Current Cancer Drug Targets